FR23C1004I2 - Antagonistes du fcrn et procédés d'utilisation - Google Patents
Antagonistes du fcrn et procédés d'utilisationInfo
- Publication number
- FR23C1004I2 FR23C1004I2 FR23C1004C FR23C1004C FR23C1004I2 FR 23C1004 I2 FR23C1004 I2 FR 23C1004I2 FR 23C1004 C FR23C1004 C FR 23C1004C FR 23C1004 C FR23C1004 C FR 23C1004C FR 23C1004 I2 FR23C1004 I2 FR 23C1004I2
- Authority
- FR
- France
- Prior art keywords
- methods
- fcrn antagonists
- fcrn
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920547P | 2013-12-24 | 2013-12-24 | |
PCT/US2014/072087 WO2015100299A1 (fr) | 2013-12-24 | 2014-12-23 | Antagonistes du fcrn et procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
FR23C1004I1 FR23C1004I1 (fr) | 2023-03-10 |
FR23C1004I2 true FR23C1004I2 (fr) | 2024-01-05 |
Family
ID=52347464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR23C1004C Active FR23C1004I2 (fr) | 2013-12-24 | 2023-01-12 | Antagonistes du fcrn et procédés d'utilisation |
Country Status (23)
Country | Link |
---|---|
US (3) | US10316073B2 (fr) |
EP (2) | EP3626738A1 (fr) |
JP (2) | JP6554473B2 (fr) |
KR (3) | KR20220152546A (fr) |
CN (2) | CN106103476B (fr) |
AU (1) | AU2014369999B2 (fr) |
BR (1) | BR112016014810B1 (fr) |
CA (1) | CA2934644C (fr) |
DK (1) | DK3087095T3 (fr) |
EA (1) | EA035324B1 (fr) |
ES (1) | ES2742682T3 (fr) |
FI (1) | FIC20230003I1 (fr) |
FR (1) | FR23C1004I2 (fr) |
HU (2) | HUE046822T2 (fr) |
IL (1) | IL246223B (fr) |
LT (2) | LT3087095T (fr) |
MX (1) | MX368804B (fr) |
NL (1) | NL301203I2 (fr) |
NZ (1) | NZ722055A (fr) |
PL (1) | PL3087095T3 (fr) |
PT (1) | PT3087095T (fr) |
SG (2) | SG10202009832XA (fr) |
WO (1) | WO2015100299A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3087095T (pt) | 2013-12-24 | 2019-10-09 | Argenx Bvba | Antagonistas de fcrn e métodos de utilização |
EA038178B1 (ru) * | 2015-03-09 | 2021-07-20 | Ардженкс Бвба | СПОСОБЫ УМЕНЬШЕНИЯ УРОВНЯ Fc-СОДЕРЖАЩИХ АГЕНТОВ В СЫВОРОТКЕ С ПРИМЕНЕНИЕМ FcRn-АНТАГОНИСТОВ |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
EP3257866A1 (fr) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire |
KR20190039937A (ko) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
AU2017366674A1 (en) | 2016-12-02 | 2019-06-20 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
KR20190141659A (ko) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | 항-apoc3 항체 및 이의 사용 방법 |
WO2019087115A1 (fr) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anticorps anti-apoc3 et leurs procédés d'utilisation |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
SG11202003944WA (en) * | 2017-12-08 | 2020-06-29 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
AU2019283673B2 (en) * | 2018-06-08 | 2023-12-07 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
MX2021000788A (es) * | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor de fc (fcrn). |
WO2020054979A1 (fr) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Composition comprenant comme principe actif un inhibiteur du cd83, pour la prévention ou le traitement de la maladie de behçet |
GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
JP2022535908A (ja) * | 2019-06-07 | 2022-08-10 | アルジェニクス ビーブイ | 皮下投与に好適なFcRnインヒビターの医薬製剤 |
JP2023509195A (ja) * | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
CN117580857A (zh) | 2021-06-23 | 2024-02-20 | 美国政府(由卫生和人类服务部的部长所代表) | Apoc-ii短模拟肽及使用方法 |
WO2023139107A1 (fr) | 2022-01-18 | 2023-07-27 | argenx BV | Anticorps anti-galectine-10 |
TW202337895A (zh) | 2022-02-21 | 2023-10-01 | 比利時商阿根思公司 | 使用fcrn拮抗劑治療肌炎之方法 |
WO2023198806A1 (fr) | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | Nouvelle classe de molécules pour la clairance sélective d'anticorps |
WO2023215838A1 (fr) | 2022-05-05 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptides mimétiques d'apolipoprotéine e courte et procédés d'utilisation |
CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
CA2118508A1 (fr) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
CA2210656C (fr) | 1995-01-17 | 2011-07-05 | Brigham And Women's Hospital, Inc. | Transport transepithelial specifique de recepteurs d'immunogenes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002043658A2 (fr) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Traitement a base de fcrn pour troubles autoimmuns |
EP1370288B1 (fr) | 2000-11-20 | 2012-01-11 | Canadian Blood Services | Procede servant a traiter la thrombocytopenie au moyen d'immunoglobuline intraveineuse monoclonale |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
WO2003011878A2 (fr) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
JP3945281B2 (ja) | 2002-03-19 | 2007-07-18 | 富士ゼロックス株式会社 | 画像形成装置 |
DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
CA2513025A1 (fr) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | Systeme vectoriel a double expression servant a exprimer des anticorps dans des cellules bacteriennes et mammiferes |
BRPI0406724A (pt) | 2003-01-13 | 2005-12-20 | Macrogenics Inc | Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2006035600A1 (fr) | 2004-09-30 | 2006-04-06 | Brother Kogyo Kabushiki Kaisha | Appareil de communication d’étiquette sans fil, étiquette sans fil, système de communication d’étiquette sans fil et méthode de communication sans fil |
JP2008538919A (ja) * | 2005-04-29 | 2008-11-13 | ザ ジャクソン ラボラトリー | FcRn抗体およびその使用 |
EP1896503B1 (fr) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | ANTICORPS D'ISOTYPE IgG1 MUTÉS DANS LEUR PARTIE Fc AFIN D'AUGMENTER LEUR LIAISON AVEC LE FcRn ET LEUR UTILISATION |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
CA2682605A1 (fr) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Fc a chaine simple, procedes de fabrication et procedes de traitement |
WO2008143954A2 (fr) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants |
US8680237B2 (en) * | 2007-06-01 | 2014-03-25 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
WO2009070748A1 (fr) | 2007-11-27 | 2009-06-04 | Umber Systems | Système pour collecter et analyser des données relatives à une activité de niveau application sur un réseau de données mobile |
US20110059091A1 (en) * | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
KR101634719B1 (ko) * | 2008-04-25 | 2016-06-29 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
US20100048488A1 (en) | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
EP2233500A1 (fr) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Variantes Fc optimisées |
DK2486141T3 (en) | 2009-10-07 | 2018-04-23 | Macrogenics Inc | FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE |
GB201111291D0 (en) | 2011-06-30 | 2011-08-17 | Agco Int Gmbh | Engine control system |
US9790280B2 (en) | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
WO2013074598A1 (fr) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Polypeptides contenant fc ayant des propriétés anti-inflammatoires améliorées et une liaison améliorée à fcrn |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
CA3188124A1 (fr) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Systeme d'expression et de secretion |
KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
ES2909014T3 (es) | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Composiciones y métodos para modular una respuesta inmunitaria |
PT3087095T (pt) | 2013-12-24 | 2019-10-09 | Argenx Bvba | Antagonistas de fcrn e métodos de utilização |
PT3193930T (pt) | 2014-09-17 | 2019-09-24 | Affibody Ab | Novos polipéptidos |
CN113384693A (zh) | 2015-01-30 | 2021-09-14 | 动量制药公司 | Fcrn抗体及其使用方法 |
EA038178B1 (ru) | 2015-03-09 | 2021-07-20 | Ардженкс Бвба | СПОСОБЫ УМЕНЬШЕНИЯ УРОВНЯ Fc-СОДЕРЖАЩИХ АГЕНТОВ В СЫВОРОТКЕ С ПРИМЕНЕНИЕМ FcRn-АНТАГОНИСТОВ |
CN108025066B (zh) | 2015-05-12 | 2022-04-12 | Synt免疫公司 | 人源化亲和力成熟的抗FcRn抗体 |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
EP3325004A1 (fr) | 2015-07-17 | 2018-05-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Méthodes et compositions pharmaceutiques pour induire une tolérance immunitaire par vaccination par voie muqueuse avec des antigènes couplés à fc |
CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
GB201618424D0 (en) | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
SG11202003944WA (en) | 2017-12-08 | 2020-06-29 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
AU2019283673B2 (en) | 2018-06-08 | 2023-12-07 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
US20220298241A1 (en) | 2019-05-17 | 2022-09-22 | Alexion Pharmaceuticals, Inc. | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases |
-
2014
- 2014-12-23 PT PT148273725T patent/PT3087095T/pt unknown
- 2014-12-23 DK DK14827372T patent/DK3087095T3/da active
- 2014-12-23 NZ NZ722055A patent/NZ722055A/en unknown
- 2014-12-23 CN CN201480070435.1A patent/CN106103476B/zh active Active
- 2014-12-23 EP EP19189186.0A patent/EP3626738A1/fr active Pending
- 2014-12-23 US US14/580,771 patent/US10316073B2/en active Active
- 2014-12-23 CN CN202010983097.8A patent/CN112142843A/zh active Pending
- 2014-12-23 CA CA2934644A patent/CA2934644C/fr active Active
- 2014-12-23 KR KR1020227034365A patent/KR20220152546A/ko not_active Application Discontinuation
- 2014-12-23 PL PL14827372T patent/PL3087095T3/pl unknown
- 2014-12-23 BR BR112016014810-0A patent/BR112016014810B1/pt active IP Right Grant
- 2014-12-23 KR KR1020167020339A patent/KR102452173B1/ko active IP Right Grant
- 2014-12-23 HU HUE14827372A patent/HUE046822T2/hu unknown
- 2014-12-23 ES ES14827372T patent/ES2742682T3/es active Active
- 2014-12-23 WO PCT/US2014/072087 patent/WO2015100299A1/fr active Application Filing
- 2014-12-23 MX MX2016008399A patent/MX368804B/es active IP Right Grant
- 2014-12-23 EP EP14827372.5A patent/EP3087095B1/fr active Active
- 2014-12-23 AU AU2014369999A patent/AU2014369999B2/en active Active
- 2014-12-23 JP JP2016542697A patent/JP6554473B2/ja active Active
- 2014-12-23 LT LTEP14827372.5T patent/LT3087095T/lt unknown
- 2014-12-23 EA EA201691304A patent/EA035324B1/ru unknown
- 2014-12-23 KR KR1020247006088A patent/KR20240033084A/ko active Search and Examination
- 2014-12-23 SG SG10202009832XA patent/SG10202009832XA/en unknown
- 2014-12-23 SG SG11201605203UA patent/SG11201605203UA/en unknown
-
2016
- 2016-06-14 IL IL246223A patent/IL246223B/en unknown
-
2017
- 2017-11-22 US US15/821,104 patent/US11505585B2/en active Active
-
2019
- 2019-01-10 JP JP2019002272A patent/JP2019076103A/ja active Pending
-
2022
- 2022-02-15 US US17/672,346 patent/US20220275035A1/en active Pending
- 2022-11-03 NL NL301203C patent/NL301203I2/nl unknown
- 2022-11-15 LT LTPA2022014C patent/LTPA2022014I1/lt unknown
- 2022-11-21 HU HUS2200048C patent/HUS2200048I1/hu unknown
-
2023
- 2023-01-12 FR FR23C1004C patent/FR23C1004I2/fr active Active
- 2023-01-19 FI FIC20230003C patent/FIC20230003I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1004I2 (fr) | Antagonistes du fcrn et procédés d'utilisation | |
IL280155A (en) | Anti- SIGLEC-8 antibodies and methods of using them | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
HK1217428A1 (zh) | 取代的苯並噁唑及其使用方法 | |
IL245844A0 (en) | Converted benzamides and methods of using them | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
DK2994488T3 (da) | Anvendelse af c5ar-antagonister | |
CL2016000235A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
MA45573A (fr) | Anticorps anti-cd154 et procédés d'utilisation correspondant | |
MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
MA45326A (fr) | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation | |
TH1601003401A (th) | แอนทิบอดีแอนทิ-dpep3 ที่ใหม่และวิธีการของการใช้งาน | |
TH1401001265B (th) | วิธีการและเครื่องสังเกตการณ์ความผิดปกติของพัฒนาการของไวรัส | |
UA27219S (uk) | Форматор-вулканізатор 75" та 88" | |
FR3006680B1 (fr) | Entonnoir rapide d'utilite collective | |
TH1401007851A (th) | อนุภาคโพลีเมอร์และลักษณะการใช้งานนั้น | |
TH1401007376A (th) | ไดอะซาสไปโรไซโคลแอลเคนและอะซาสไปโรไซโคลแอลเคนชนิดใหม่ | |
TH1401005254B (th) | สารผสมของสารยึดติดโพลีโอเลฟิน และวิธีการของการเตรียมสารผสม | |
TH1501000633B (th) | อุปกรณ์การทำงาน และตู้แช่แข็ง-ตู้เย็น |